Since the approval of the cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) inhibitor ipilimumab for the treatment of metastatic melanoma in 2011, immune checkpoint inhibitors (ICPI) have become a cornerstone in the treatment of solid malignancies [1]. Here, CTLA4 is linked to metastatic melanoma.